{"id":"NCT01849497","sponsor":"Amgen","briefTitle":"Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen","officialTitle":"A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a Prefilled Syringe or a Prefilled Autoinjector/Pen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-18","primaryCompletion":"2013-09-02","completion":null,"firstPosted":"2013-05-08","resultsPosted":"2015-10-09","lastUpdate":"2018-11-29"},"enrollment":149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab Pre-filled Syringe","otherNames":["AMG 145","Repatha"]},{"type":"BIOLOGICAL","name":"Evolocumab AI/pen","otherNames":["AMG 145","Repatha"]}],"arms":[{"label":"Evolocumab PFS","type":"EXPERIMENTAL"},{"label":"Evolocumab AI/pen","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.","primaryOutcome":{"measure":"Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4","timeFrame":"Week 2 and Week 4","effectByArm":[{"arm":"Evolocumab PFS","deltaMin":96,"sd":null},{"arm":"Evolocumab AI/Pen","deltaMin":89.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":26,"countries":["United States","Canada"]},"refs":{"pmids":["28717862","28249876","29353350","27066336"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":75},"commonTop":["Headache"]}}